HC Wainwright Has Weak Forecast for Humacyte FY2029 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Analysts at HC Wainwright decreased their FY2029 earnings estimates for Humacyte in a report issued on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.07 for the year, down from their prior estimate of $0.09. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Humacyte’s FY2030 earnings at $0.29 EPS.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million. Humacyte had a negative return on equity of 640.19% and a negative net margin of 3,955.05%.

A number of other research analysts also recently weighed in on HUMA. Barclays increased their target price on shares of Humacyte from $0.50 to $0.60 and gave the company an “equal weight” rating in a research report on Wednesday. Williams Trading set a $1.00 price target on shares of Humacyte in a report on Friday, October 16th. Benchmark dropped their price objective on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research note on Friday, October 2nd. Finally, Wall Street Zen lowered Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $4.98.

Humacyte Stock Up 0.3%

HUMA opened at $0.59 on Thursday. The company has a quick ratio of 5.74, a current ratio of 6.21 and a debt-to-equity ratio of 2.07. The stock has a market cap of $164.37 million, a price-to-earnings ratio of -1.34 and a beta of 2.64. Humacyte has a twelve month low of $0.34 and a twelve month high of $1.52. The company’s 50-day moving average price is $0.49 and its two-hundred day moving average price is $0.78.

Institutional Investors Weigh In On Humacyte

A number of institutional investors and hedge funds have recently modified their holdings of HUMA. Beacon Pointe Advisors LLC bought a new position in shares of Humacyte in the second quarter valued at approximately $28,000. Bank of New York Mellon Corp bought a new stake in Humacyte during the 2nd quarter worth approximately $44,000. Sei Investments Co. purchased a new stake in Humacyte in the 1st quarter worth approximately $56,000. Miramontes Capital LLC purchased a new stake in Humacyte in the 2nd quarter worth approximately $85,000. Finally, LaSalle St. Investment Advisors LLC bought a new position in Humacyte in the 2nd quarter valued at $89,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.